Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
CMS Administrator Dr. Mehmet Oz is sounding the alarm on Medicare Advantage, calling the program a "garden vulnerable to weeds and overgrowth." The Trump administration says tightening oversight is a top priority, citing insurer profiteering and ballooning costs. But most of its actual policy moves have so far favored the industry.
CMS Administrator Dr. Mehmet Oz is using garden metaphors to describe a growing problem: Medicare Advantage (MA), the privatized version of Medicare, is being exploited by insurers at taxpayers' expense. Speaking at a major MA industry event in Washington, D.C., Oz declared that strengthening the program is "one of our top priorities," citing concerns about care quality and responsible use of taxpayer dollars.
The Trump administration's tough talk, however, hasn't always matched its actions. While regulators finalized tighter guardrails on how plans account for member health risks — a move aimed at curbing "upcoding" — they also reversed proposed payment cuts, restored a more generous quality ratings system, and ended a program that helped stabilize Part D drug premiums, all moves that benefited insurers.
The stakes are enormous. More than 35 million Americans — over half of all Medicare seniors — are enrolled in MA plans, drawn by lower costs and extra perks. But the federal government is paying a steep premium for that popularity.
By the Numbers:
Why it matters: With MA costs spiraling and insurer abuses well-documented, the pressure to reform is real — but so is the political tightrope. In a midterm year, the administration must balance voter frustration over healthcare costs against its traditionally industry-friendly stance.
